title: Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
abstract: The glutathione S-transferase (GST)-L1 multiplex serology assay has favorable properties for use in clinical trials and epidemiologic studies, including low cost, high throughput capacity, and low serum volume requirement. Therefore, we evaluated the GST-L1 assay as a measure of HPV16/18 vaccine immunogenicity. Our study population included 65 women selected from the Costa Rica Vaccine Trial who received the bivalent HPV16/18 virus-like particle (VLP) vaccine at the recommended 0/1/6-month schedule. We tested replicate serum samples from months 0/1/12 (i.e., after 0/1/3 doses) by GST-L1 and 3 other commonly used serology assays, VLP-ELISA, SEAP-NA, and cLIA. We calculated the percentage of women seropositive by GST-L1 by time point and HPV type (14 HPV types), and compared GST-L1 to other assays using Spearman rank correlation coefficients. After 1 vaccine dose, seropositivity by GST-L1 was 40% each for HPV16 and HPV18, increasing to 100% and 98%, respectively, after 3 doses. Seropositivity after 3 doses ranged from 32% to 69% for HPV types 31/33/45, for which partial vaccine efficacy is reported, though increases also occurred for types with no evidence for cross-protection (e.g., HPV77). GST-L1 correlated best after 3 doses with VLP-ELISA (HPV16 and HPV18 each ρ = 0.72) and SEAP-NA (HPV16 ρ = 0.65, HPV18 ρ = 0.71) (all P < 0.001); correlation was lower with cLIA. The GST-L1 is suitable for evaluating HPV16/18 vaccine immunogenicity after 3 vaccine doses, although in contrast to other assays it may classify some samples as HPV16/18 seronegative. The assay's utility is limited for lower antibody levels such as after receipt of 1 dose.
authors.affiliation: a Division of Cancer Epidemiology and Genetics; National Cancer Institute; National Institutes of Health ; Rockville , MD USA.
authors.forename: Hilary A
authors.initials: HA
authors.lastname: Robbins
authors.forename: Tim
authors.initials: T
authors.lastname: Waterboer
authors.forename: Carolina
authors.initials: C
authors.lastname: Porras
authors.forename: Troy J
authors.initials: TJ
authors.lastname: Kemp
authors.forename: Michael
authors.initials: M
authors.lastname: Pawlita
authors.forename: Ana Cecilia
authors.initials: AC
authors.lastname: Rodriguez
authors.forename: Sholom
authors.initials: S
authors.lastname: Wacholder
authors.forename: Paula
authors.initials: P
authors.lastname: Gonzalez
authors.forename: John T
authors.initials: JT
authors.lastname: Schiller
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Lowy
authors.forename: Mark
authors.initials: M
authors.lastname: Esser
authors.forename: Katie
authors.initials: K
authors.lastname: Matys
authors.forename: Sylviane
authors.initials: S
authors.lastname: Poncelet
authors.forename: Rolando
authors.initials: R
authors.lastname: Herrero
authors.forename: Allan
authors.initials: A
authors.lastname: Hildesheim
authors.forename: Ligia A
authors.initials: LA
authors.lastname: Pinto
authors.forename: Mahboobeh
authors.initials: M
authors.lastname: Safaeian
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D000917:Antibody Formation / Q000276:immunology; D001681:Biological Assay / Q000379:methods*; D003364:Costa Rica; D056738:Cross Protection; D005260:Female; D005982:Glutathione Transferase / Q000378:metabolism; D052162:Human papillomavirus 16 / Q000276:immunology*; D052161:Human papillomavirus 18 / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D030361:Papillomavirus Infections / Q000276:immunology* / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000276:immunology*; D015203:Reproducibility of Results; D014611:Vaccination
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines; D005982:Glutathione Transferase
keywords: BKV, BK virus; CV, coefficient of variation; CVT, Costa Rica Vaccine Trial; EU/mL, ELISA units per milliliter; GST-L1 multiplex serology; GST-L1, glutathione S-transferase L1 multiplex serology assay; HPV vaccine; HPV, human papillomavirus; ICC, intraclass correlation coefficient; JCV, JC virus; LLOD, lower limit of detection; MFI, median fluorescence units; OD, optical density; SEAP-NA; SEAP-NA, secreted alkaline phosphatase neutralization assay; VLP, virus-like particle; VLP-ELISA; VLP-ELISA, virus-like particle-based enzyme linked immunosorbent assay; cLIA; cLIA, competitive Luminex immunoassay; human papillomavirus (HPV); immunogenicity assessment; mMU/mL, milli-Merck units per milliliter